…
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Qilian International Holding Group Limited (NASDAQ: BGM) are sparse and do not clearly describe the company's core operations or revenue mix. Because long-term growth drivers are not well documented, potential upside appears to hinge on management execution, segment expansion and improved public reporting. Investors may find exposure to a small-cap international holding structure attractive if operational clarity and governance strengthen.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Income before tax | -2.14M | -7.90M | 1.56M | 3.36M | 5.81M |
| Minority interest | 0.07M | 0.34M | -0.29M | 0.04M | 0.12M |
| Net income | -1.44M | -7.78M | 1.08M | 3.15M | 5.06M |
| Selling general administrative | 2.72M | 4.36M | 4.13M | 3.25M | 2.73M |
| Selling and marketing expenses | 0.59M | - | - | - | - |
| Gross profit | 4.11M | 1.75M | 6.23M | 5.64M | 7.54M |
| Reconciled depreciation | 1.24M | 1.14M | 1.22M | 1.20M | 1.17M |
| Ebit | -0.36M | - | - | - | - |
| Ebitda | 0.88M | - | - | - | - |
| Depreciation and amortization | 1.24M | - | - | - | - |
| Operating income | -0.56M | -2.42M | 2.52M | 2.95M | 5.89M |
| Other operating expenses | 25.66M | - | - | - | - |
| Interest expense | 0.64M | - | - | 0.06M | 0.24M |
| Tax provision | -0.62M | 0.22M | 0.19M | 0.26M | 0.86M |
| Interest income | - | - | 0.02M | - | - |
| Net interest income | -0.64M | 0.10M | 0.02M | -0.06M | -0.24M |
| Income tax expense | -0.62M | - | - | - | - |
| Total revenue | 25.10M | 46.47M | 64.86M | 57.10M | 50.03M |
| Total operating expenses | 4.68M | 48.89M | 62.34M | 54.15M | 44.14M |
| Cost of revenue | 20.98M | 44.72M | 58.63M | 51.46M | 42.49M |
| Total other income expense net | -1.57M | -5.58M | -0.98M | 0.47M | 0.16M |
| Net income from continuing ops | -1.52M | -8.12M | 1.37M | 3.11M | 4.94M |
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 53.00M | 51.26M | 64.53M | 75.35M | 48.14M |
| Intangible assets | 4.54M | 3.42M | 1.73M | 1.93M | 1.88M |
| Other current assets | 0.80M | - | -0.00M | - | - |
| Total liab | 8.91M | 6.91M | 9.56M | 18.68M | 19.30M |
| Total stockholder equity | 42.74M | 42.79M | 53.05M | 54.86M | 26.10M |
| Other current liab | 3.77M | - | - | - | - |
| Common stock | 0.06M | - | - | - | - |
| Capital stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.05M |
| Retained earnings | 4.35M | 5.90M | 15.51M | 14.69M | 12.20M |
| Cash | 9.82M | 7.48M | 14.32M | 10.47M | 11.87M |
| Total current liabilities | 8.78M | 6.66M | 9.18M | 18.17M | 18.42M |
| Current deferred revenue | 0.57M | - | - | - | - |
| Net debt | -9.82M | - | - | - | - |
| Short long term debt | - | 0.48M | 1.67M | 7.87M | 7.35M |
| Other stockholder equity | 36.41M | - | - | - | - |
| Total current assets | 29.77M | 34.51M | 30.03M | 40.37M | 37.52M |
| Long term investments | 3.36M | 0.61M | 20.09M | 20.96M | 0.54M |
| Short term investments | 8.32M | 14.94M | 0.00M | - | - |
| Net receivables | 5.77M | 1.98M | 0.82M | 1.73M | 1.12M |
| Inventory | 5.05M | 4.99M | 8.88M | 12.50M | 11.99M |
| Accounts payable | 4.13M | 3.59M | 5.29M | 6.64M | 4.38M |
| Accumulated other comprehensive income | 1.92M | - | - | - | - |
| Non currrent assets other | - | - | 0.17M | 0.19M | 0.18M |
| Non current assets total | 23.23M | 16.75M | 34.49M | 34.99M | 10.63M |
| Capital lease obligations | 0.00M | 0.10M | 0.10M | 0.16M | 0.24M |
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Investments | 0.98M | -4.74M | -3.26M | -24.20M | -0.38M |
| Total cashflows from investing activities | 0.98M | - | - | - | - |
| Net borrowings | -0.49M | - | - | - | - |
| Total cash from financing activities | -0.49M | -2.92M | -5.94M | 23.99M | 2.14M |
| Net income | -1.52M | -7.78M | 1.08M | 3.15M | 5.06M |
| Change in cash | 2.34M | -7.50M | 2.37M | 0.74M | 7.27M |
| Begin period cash flow | 7.48M | 14.98M | 12.61M | 11.87M | 4.59M |
| End period cash flow | 9.82M | 7.48M | 14.98M | 12.61M | 11.87M |
| Total cash from operating activities | 0.54M | 0.31M | 12.65M | 0.35M | 5.08M |
| Issuance of capital stock | - | 0.00M | 0.00M | 23.87M | 0.00M |
| Depreciation | 1.24M | 1.14M | 1.22M | 1.20M | 1.17M |
| Other cashflows from investing activities | -1.02M | - | - | - | - |
| Dividends paid | 0.00M | 1.79M | 0.00M | - | 0.00M |
| Change to inventory | 0.96M | 3.40M | 2.23M | 0.05M | 1.40M |
| Change to account receivables | 1.33M | -1.22M | 1.03M | -0.55M | -0.66M |
| Capital expenditures | 3.93M | 3.71M | 3.26M | 3.49M | 0.46M |
| Change in working capital | 0.79M | 1.11M | 8.75M | -3.67M | -0.79M |
| Stock based compensation | 0.00M | 0.00M | 0.02M | 0.00M | 0.00M |
| Other non cash items | 0.45M | 0.03M | 0.02M | 0.06M | - |
| Free cash flow | -3.39M | -3.40M | 9.40M | -3.15M | 4.62M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BGM BGM Group Ltd. |
- -% |
8.01 | - | - | 0.26 | 0.40 | 2.25 | -2.48 |
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.
No. 152 Hongliang East 1st Street, Chengdu, China, 610200
86 28 6477 5180
298
| Name | Title | Year Born |
|---|---|---|
| Mr. Zhanchang Xin | Chairman of the Board, President, COO & Chief Scientific Officer | 1967 |
| Mr. Chen Xin | Chief Executive Officer | 1993 |
| Ms. Yaxuan Zhai | Chief Financial Officer | 1995 |
| Mr. Chen Xin | CEO, VP of Duxiaobao Management Committee & Chairman | 1994 |
| Mr. Yuqing Li | Co-Chief Executive Officer | NA |
| Ms. Yaxuan Zhai | Chief Financial Officer | 1996 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.